AdaptHealth Corp vs Lockheed Martin Corporation — how do they compare? AdaptHealth Corp trades at $5.79 (market cap $753.09M), while Lockheed Martin Corporation trades at $604.06 (market cap $137.96B). The key difference: Lockheed Martin Corporation is far larger — about 183.2× AdaptHealth Corp's market cap, and Lockheed Martin Corporation pays a 2.31% dividend while AdaptHealth Corp pays none. Which is the better fit depends on your goals.
| AHCO | LMT | |
|---|---|---|
Market Cap | $753.09M | $137.96B |
Sector | Health | Industrials |
52-Week High | $13.38 | $676.70 |
52-Week Low | $5.22 | $431.56 |
Enterprise Value | $2.77B | $154.71B |
Dividend Yield | — | 2.31% |
Signals from Pluang's Aura AI — not financial advice
AdaptHealth (AHCO) trades at $5.63, up 7.85% today but remains under significant pressure after recent earnings disappointments. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal negative profitability with a -6.82% net margin and three consecutive quarterly earnings misses. The company is restructuring by selling its diabetes unit to focus on sleep and respiratory care, but faces multiple securities fraud investigations following guidance revisions.
Despite 75% analyst buy ratings and an $11 consensus price target suggesting 95% upside, substantial risks exist including ongoing legal probes, execution challenges with new fixed-price contracts, and negative cash flow trends. The stock presents high-risk speculation amid operational restructuring and legal uncertainties.
Lockheed Martin (LMT) trades at $601.99, down 0.19% on the day, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with a record $230.4 billion backlog (Seeking Alpha, 2026-08-04), revenue growth to $75.05 billion in 2025, and a net income margin of 8.16%. Recent news highlights major defense contracts, including a $53.9 billion Patriot missile order (The Motley Fool, 2026-08-11), supporting long-term growth.
The outlook for LMT is positive, driven by expanding defense budgets and execution on its backlog, though risks include earnings misses and debt levels. Analysts project a consensus price target of $608, with 57% recommending buy. The stock's valuation metrics, such as a P/E of 22.04, appear reasonable given growth prospects, but investors should monitor contract execution and macroeconomic pressures.
Trailing returns across standard periods
Latest headlines on both assets
AdaptHealth provides patient-centered healthcare-at-home solutions in the U.S. It offers medical equipment and supplies for sleep therapy, respiratory health, diabetes management, and general home wellness.
Read more on AHCO →Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →